![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
KB Home
KBH
4
Taylor Morrison Home
TMHC
5
Ecopetrol
EC
US Stock MarketDetailed Quotes
CHRS Coherus BioSciences
- 0.838
- -0.013-1.54%
Trading Mar 28 14:03 ET
97.11MMarket Cap3.35P/E (TTM)
0.888High0.830Low811.06KVolume0.860Open0.851Pre Close686.40KTurnover0.71%Turnover Ratio3.35P/E (Static)115.90MShares2.61052wk High-0.74P/B95.87MFloat Cap0.66052wk Low--Dividend TTM114.41MShs Float38.100Historical High--Div YieldTTM6.82%Amplitude0.660Historical Low0.846Avg Price1Lot Size
Coherus BioSciences Stock Forum
Sign in to post a comment
$Coherus BioSciences (CHRS.US)$
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial
2
1
$Coherus BioSciences (CHRS.US)$
Upon the completion of the Udenyca divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million,” Coherus CEO Denny Lanfear said in the release. “These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026.”
This clinical-s...
Upon the completion of the Udenyca divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million,” Coherus CEO Denny Lanfear said in the release. “These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026.”
This clinical-s...
2
$Coherus BioSciences (CHRS.US)$ Embrace this, the convertible bond shorties going to be squeeze soon!
2
$Coherus BioSciences (CHRS.US)$
Net income (loss) for the fourth quarter of 2024 was a net loss of $50.7 million, or $(0.44) per share on a diluted basis, compared to a net loss of $79.7 million, or $(0.71) per share on a diluted basis for the same period in 2023.
Net income for the year ended December 31, 2024 was $28.5 million, or $0.25 per share on a diluted basis, compared to a net loss of $237.9 million, or $(2.53) per share on a diluted basis for year ended December 31, 202...
Net income (loss) for the fourth quarter of 2024 was a net loss of $50.7 million, or $(0.44) per share on a diluted basis, compared to a net loss of $79.7 million, or $(0.71) per share on a diluted basis for the same period in 2023.
Net income for the year ended December 31, 2024 was $28.5 million, or $0.25 per share on a diluted basis, compared to a net loss of $237.9 million, or $(2.53) per share on a diluted basis for year ended December 31, 202...
$Foremost Lithium Resource & Technology (FMST.US)$ $MicroCloud Hologram (HOLO.US)$ $Hepion Pharmaceuticals (HEPA.US)$ $Allarity Therapeutics (ALLR.US)$ $SAB Biotherapeutics (SABS.US)$ $Blue Hat Interactive Entertainment Technology (BHAT.US)$ $ChargePoint (CHPT.US)$ $Greenwave Technology Solutions (GWAV.US)$ $Utime (WTO.US)$ $N2OFF (NITO.US)$ $Intrusion (INTZ.US)$ $Coherus BioSciences (CHRS.US)$ $Aditxt (ADTX.US)$ $Nauticus Robotics (KITT.US)$
Top Watch for Monday 1/27
$HOLO (1.56) Inv. Hammer Fri
$HEPA (.19c) Big move com...
Top Watch for Monday 1/27
$HOLO (1.56) Inv. Hammer Fri
$HEPA (.19c) Big move com...
5
$Tevogen Bio Holdings (TVGN.US)$ $1847 Holdings (EFSH.US)$ $TruGolf (TRUG.US)$ $3D Systems (DDD.US)$ $SES AI Corp (SES.US)$ $Aclarion (ACON.US)$ $Stardust Power (SDST.US)$ $Coherus BioSciences (CHRS.US)$ $Twilio (TWLO.US)$ $Nvni Group (NVNI.US)$ $PainReform (PRFX.US)$ $Avenue Therapeutics (ATXI.US)$ $Dogwood Therapeutics (DWTX.US)$ $Evaxion Biotech (EVAX.US)$ $Starbox Group (STBX.US)$ $Allurion Technologies (ALUR.US)$
📊⚡️📊
📊⚡️📊
3
$Coherus BioSciences (CHRS.US)$
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
2
2
No comment yet
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
CoolWaterCoolWater :
. Sure bo?
Barclays analyst Balaji Prasad maintains $Coherus BioSciences (CHRS.US)$ with a buy rating, and maintains the target price at $7.